Odomzo (sonidegib) — CareFirst (Caremark)
Locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or in patients who are not candidates for surgery or radiation therapy
Initial criteria
- Member is an adult (age ≥ 18 years)
- Drug is used as a single agent for treatment of locally advanced or diffuse (e.g., Gorlin syndrome) basal cell carcinoma
Reauthorization criteria
- Member has no evidence of unacceptable toxicity while on therapy
- Member has no disease progression while receiving therapy
Approval duration
12 months